Psychosocial Interventions and Functional Recovery in Schizophrenia—Realizing Opportunities Today

Rajiv Tandon, MD; Deanna M. Barch, PhD; Robert W. Buchanan, MD; Michael F. Green, PhD; Matcheri S. Keshavan, MD; Stephen R. Marder, MD; Henry A. Nasrallah, MD; and Antonio Vita, MD, PhD

This Academic Highlights section of *The Journal of Clinical Psychiatry* presents the highlights of the virtual consensus panel meeting "Psychosocial Interventions and Functional Recovery in Schizophrenia—Realizing Opportunities Today," which was held June 2, 2025.

The meeting was chaired by **Rajiv Tandon, MBBS, MD, MS**, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan (correspondence: rajiv.tandon@wmed.edu; 211 Langley Road, Newton, MA 02459). The faculty were **Deanna M. Barch, PhD**, Washington University, Saint Louis, Missouri; **Robert W. Buchanan, MD**, University of Maryland School of Medicine, Baltimore, Maryland; **Michael F. Green, PhD**, University of California, Los Angeles, California; **Matcheri S. Keshavan, MD**, Beth Israel Deaconess Medical Center, Boston, Massachusetts; **Stephen R. Marder, MD**, University of California, Los Angeles, California; **Henry A. Nasrallah, MD,** University of Cincinnati Neuroscience Institute, Cincinnati, Ohio; and **Antonio Vita, MD, PhD**, University of Brescia, Brescia, Italy.

Financial disclosures appear at the end of the article.

This evidence-based, peer-reviewed Academic Highlights article was prepared by Healthcare Global Village, Inc. The consensus panel meeting on which this manuscript is based was funded by Boehringer-Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut. The sponsor had no role in the writing, review, or submission of this manuscript. The authors, with support from Healthcare Global Village, Inc., drafted and submitted the article for peer review. Article processing charges, medical writing, editorial, and other assistance were funded by Healthcare Global Village, Inc. Editorial support was provided by P. Benjamin Everett, PhD, Healthcare Global Village, Inc. The opinions expressed herein are those of the faculty and do not necessarily reflect the views of Healthcare Global Village, Inc., the publisher, or the commercial sponsor. This article is distributed by Healthcare Global Village, Inc. for educational purposes only.

Published Online: December 5, 2025.

To Cite: Tandon R, Barch DM, Buchanan RW, et al. Psychosocial interventions and functional recovery in schizophrenia—realizing opportunities today. *J Clin Psychiatry.* 2025;86(4):hfrecachi2505

To Share: https://doi.org/10.4088/JCP.hfrecachi2505

ABSTRACT

Functional recovery has emerged as a critical treatment goal in schizophrenia, extending beyond symptom reduction to encompass independent living, vocational and educational attainment, social integration, and overall quality of life. Despite advances in pharmacotherapy, many people with schizophrenia continue to experience significant functional impairments driven by persistent symptoms, cognitive deficits, comorbidities, stigma, and adverse social determinants. Psychosocial interventions have been shown to be effective in improving functional outcomes but are not extensively utilized. To address these challenges, a consensus panel of experts in psychiatry and psychology reviewed the evidence base and developed practical recommendations for optimizing functional outcomes.

Panel discussions highlighted 4 domains of functional drivers in schizophrenia: intrinsic, behavioral, comorbid/consequential, and societal/contextual, and evaluated psychosocial interventions with demonstrated benefits relative to these domains. Amidst lingering questions about further refinement and optimal individualization, evidence clearly supports the use of cognitive behavioral therapy, cognitive remediation, social skills training, supported employment and housing, and family-focused interventions; likewise, evidence supports the use of psychoeducation, motivational interviewing, mindfulness- and acceptance-based therapies, and lifestyle interventions, such as structured exercise. Implementation remains limited due to workforce shortages, resource constraints, and a lack of integration into routine care.

The panel recommends a comprehensive, patient-centered approach that integrates pharmacological treatment with evidence-based psychosocial strategies, guided by measurement-based care and individualized treatment planning. Validated functional assessment tools and emerging digital therapeutics offer scalable methods to monitor and enhance outcomes. By addressing both intrinsic and extrinsic drivers of disability, clinicians can more effectively support people with schizophrenia in achieving functional recovery and an improved quality of life.

J Clin Psychiatry 2025;86(4):hfrecachi2505

INTRODUCTION

Schizophrenia is a lifelong condition and a leading cause of global disability, imposing substantial health, social, and financial burdens on individuals, caregivers, and systems of care.[1–3] Schizophrenia presents with a spectrum of positive symptoms, negative symptoms, and cognitive impairments.[4–10] The primary treatment goal in schizophrenia is to enable recovery, broadly

Figure 1.
Optimizing Recovery for Patients With Schizophrenia



Abbreviations: CBT=cognitive behavioral therapy, SDOH=social determinants of health, SES=socioeconomic status, SUD=substance use disorder.

defined as the ability of an individual with schizophrenia to lead a productive and personally meaningful life.[11,12] The objective of treatment is to optimally facilitate the individual's ability to do so in the face of living with schizophrenia. To accomplish this, we need to develop individualized, patient-centered care that adapts across the illness spectrum (first episode vs multi-episode).

Pharmacological treatment remains the foundation of management, but it is limited by incomplete symptom control, adverse effects, and nonadherence.[7,10–14] Accordingly, evidence-based psychosocial and rehabilitation interventions are essential to comprehensive care.[13,14] Yet, functional outcomes remain poor for myriad reasons, including modest effect sizes of currently available psychosocial tools; underutilization of psychosocial tools due to limited access, workforce shortages, training gaps, and systemic underinvestment; and clinical inertia fostered by low expectations and therapeutic nihilism.[15–18] Closing this gap requires renewed emphasis on individualized, measurement-based care that addresses all symptom domains and the broader determinants of functional recovery.[19,20]

In June 2025, a multidisciplinary panel of 8 experts in psychiatry, psychology, and psychosocial research was convened to evaluate key drivers of functional impairment and to review psychosocial and psychotherapeutic interventions that promote functional recovery. Through structured discussions, the panel integrated evidence and clinical expertise to identify functional drivers, align interventions with targeted domains, and develop consensus-based recommendations for optimizing care delivery.

To guide this effort, the panel adopted a framework, which categorized drivers of impairment into 4 domains: intrinsic, behavioral, comorbid/consequential, and societal/contextual (**Table 1**). These domains served as the foundation for evaluating how different psychosocial interventions may target distinct contributors to functional disability. **Figure 1** illustrates this functional framework, highlighting how pharmacological treatment, rehabilitation strategies, and supportive services may act independently, additively, or potentially synergistically, to reduce burden and enhance recovery. The figure also acknowledges that all interventions carry inherent costs or burdens that may offset gains. The sections that follow revisit this model in depth, elaborating on how it informs the selection and integration of psychosocial interventions across functional domains. Of note, systemic barriers were also discussed as drivers of disability and are discussed briefly; however, as these barriers are not directly related to the underlying disease pathology, they are discussed separately.

Table 1.

Drivers of Functional Impairment in Schizophrenia

Domain	Driver of functional impairment	Definition	Mechanisms/contributing factors	Functional consequences	Evidence-based interventions	Key references
Intrinsic (symptoms and core features of illness)	**Negative symptoms**	Diminished or absent emotional expression, speech output, motivation, goal-directed behavior, pleasure, and/or social engagement. Core domains include avolition, anhedonia, asociality, alogia, and blunted affect	May reflect primary illness pathology or be secondary to depression, medication effects, or environmental deprivation. Neurobiological underpinnings involve frontostriatal and mesolimbic circuit dysfunction, dopamine hypoactivity, and impaired reward processing	Markedly reduced initiation and persistence of activity, social withdrawal, poor occupational and educational attainment, and diminished capacity to benefit from rehabilitation or psychosocial interventions	• CBT targeting motivational deficits • Behavioral activation • Social skills training • Supported employment and education • Family psychoeducation	• Barch et al[7] • Govil and Kantrowit[8]
	Cognitive impairment	Deficits in neurocognition (eg, processing speed, attention, working memory, learning, reasoning, problem-solving) and/or social cognition (eg, emotion recognition, theory of mind, attributional style)	Neurodevelopmental abnormalities; disrupted frontotemporal and frontoparietal connectivity; illness-related factors (untreated psychosis, anticholinergic burden, comorbid depression or SUD); relatively stable over illness course	Limits skill acquisition, problem-solving, and adaptive functioning; reduces success in employment, education, and independent living; hinders social integration and rehabilitation engagement	• CRT • Social cognitive training • Metacognitive approaches • Compensatory strategy training • Combined CRT with supported employment or social skills training • Digital/computerized cognitive training	• McCutcheon et al[34] • Gebreegziabhere et al[36]
	Diminished insight	Impaired awareness of having a mental illness, the need for treatment, and/or the severity of symptoms	Multifactorial: illness-related cognitive deficits (esp. executive dysfunction, self-monitoring), negative symptom burden, neurobiological alterations in self-reflective processes, co-occurring stigma and denial	Poor adherence to pharmacologic and psychosocial treatments; higher relapse and hospitalization rates; reduced engagement with rehabilitation; exacerbates other drivers (eg, uncontrolled positive symptoms, social isolation)	• Psychoeducation (patient and family) • Motivational interviewing • CBT for psychosis • Metacognitive training (select approaches) • Integrated care with family involvement and adherence supports	• Roux et al[39] • Sakai et al[40]
Behavioral	**Lack of adherence**	Partial or complete failure to follow prescribed pharmacologic or psychosocial treatment plans	Diminished insight, adverse effects, cognitive deficits, substance use, stigma, logistical barriers (transportation, cost), lack of support, limited therapeutic alliance	Increased relapse and hospitalization; worsening symptoms; reduced likelihood of recovery; progressive functional decline; higher healthcare costs	• Shared decision-making and collaborative goal-setting • Long-acting injectable antipsychotics • Psychoeducation (patient and family) • Adherence therapy and motivational interviewing • Digital adherence tools (reminders, monitoring) • Case management and peer support	• Semahegn et al[45] • Kane et al 2013[46]
	Alcohol and/or substance abuse	Co-occurring misuse of alcohol, cannabis, stimulants, opioids, or other substances that worsens illness stability, treatment adherence, symptom control, and overall functioning	Substances exacerbate positive symptoms, impair cognition, interact negatively with antipsychotic treatment, and reduce adherence, while biological vulnerability, environmental stressors, and limited coping resources increase risk for use	AUD/SUD contribute to relapse, rehospitalization, impaired social and occupational functioning, homelessness, legal involvement, and reduced capacity to engage in rehabilitation or maintain independent living	• Integrated dual-diagnosis treatment, motivational interviewing, CBT for substance use, contingency management • Use of long-acting injectables to support adherence alongside supported employment or housing when appropriate	• Nesvag et al[50] • Chesney et al[52] • Hasan et al[57]

(continued)

Table 1 (continued).

Domain	Driver of functional impairment	Definition	Mechanisms/contributing factors	Functional consequences	Evidence-based interventions	Key references
Comorbid / consequential	**Depressive symptoms and defeatist beliefs**	Presence of low mood, hopelessness, anhedonia, guilt, or suicidal ideation, often accompanied by maladaptive self-schemas characterized by low self-worth and pessimism	May arise as part of acute psychotic episodes, post-psychotic depression, or chronic comorbid mood disorder. Contributing factors include illness-related neurobiological changes, maladaptive cognitions, stigma, repeated functional failures, and social isolation	Reduced motivation and engagement in treatment; impaired goal setting and follow-through; poorer social and occupational functioning; increased relapse risk and suicidality; perpetuation of inactivity and disengagement	• CBT targeting negative thoughts and beliefs • Behavioral activation • Social skills training to improve self-efficacy • Supported employment employment and education education to foster mastery • Pharmacologic treatment of comorbid depression	• Li et al[60] • Krynicki et al[61] • Campellone et al[65] • Grant and Beck[66]
	Loneliness/social isolation	Loneliness: subjective distress from a perceived gap between desired and actual social relationships. Social isolation: objective lack of social contact or network ties	Negative symptoms, cognitive and social cognitive deficits, stigma, functional setbacks, socioeconomic disadvantage, housing instability, limited community support	Reduced quality of life; poorer functional recovery; increased depression and relapse risk; higher mortality	• Social skills training • Supported employment and education • Peer-led programs and community engagement initiatives • Group-based CBT or social cognitive training • Digital peer support platforms	• Yu et al[21] • Hajek et al[68] • Green et al[70]
	Internalized stigma	Internalized stigma refers to the adoption of negative societal beliefs about mental illness, leading individuals with schizophrenia to experience shame, diminished self-worth, and reduced expectations for recovery	Self-stigma develops through repeated exposure to public stigma, perceived discrimination, social withdrawal, and depressive or demoralized thinking patterns, which undermine self-efficacy and motivation	Internalized stigma reduces engagement in treatment; worsens depressive symptoms; limits pursuit of social, vocational, and educational goals; and reinforces isolation, ultimately impeding functional recovery	• CBT targeting self-stigmatizing beliefs, narrative enhancement and cognitive therapy • Structured psychoeducation, peer-support models, and recovery-oriented psychosocial rehabilitation that builds mastery and self-efficacy	• Dubreucq et al[74] • Barlati et al 2022[76] • Gagiu et al[79]
Societal / Contextual	**Discrimination/ external stigma**	Negative stereotypes, prejudice, and discrimination toward individuals with schizophrenia; includes societal (*public*) stigma	Discriminatory attitudes and behaviors from others, reinforced by structural barriers	Reduced treatment engagement; avoidance of employment, education, and social opportunities; increased isolation; exacerbation of depressive symptoms and self-defeating beliefs	• Public education campaigns • Contact-based interventions • Peer-led support and empowerment programs • CBT to address internalized stigma • Workplace anti-discrimination policies and advocacy	• Parcesepe and Cabass[73] • Dubreucq et al[74]
	Social determinants of health and socioeconomic status	Non-medical factors that shape health outcomes, including socioeconomic, environmental, and community conditions	Poverty, unstable housing, limited education, unsafe neighborhoods, food insecurity, inadequate healthcare access, health literacy deficits, discrimination, and structural inequities	Reduced treatment engagement, increased symptom burden, poorer functional outcomes, higher relapse and hospitalization risk	• Supported housing • Transportation assistance • Community-based case management • Food and nutrition programs • Legal and benefits advocacy • Integration of social service referrals into clinical care	• Hatzenbuehle[84] • Jeste et al[87] • Kirkbride et al 2024[89] • Barry et al[91] • Correll et al[92]
		The economic disadvantage, poverty, unemployment, and housing instability disproportionately experienced by individuals with schizophrenia	Illness-related functional limitations, stigma, workplace discrimination, limited education, interrupted vocational/academic progress, lack of affordable housing, structural poverty	Reduced access to food, housing, transportation; increased stress and symptom exacerbation; poorer treatment adherence; higher risk of homelessness; greater healthcare utilization and disability claims	• Supported employment (IPS) • Supported education • Supported housing • Benefits counseling and vocational rehabilitation • Case management and peer support • Policy advocacy for income and housing supports	

(continued)

Table 1 (continued).

Domain	Driver of functional impairment	Definition	Mechanisms/contributing factors	Functional consequences	Evidence-based interventions	Key references
Societal/ Contextual	Lack of family or caregiver support	Absence or insufficiency of consistent emotional, practical, and advocacy support from family members or caregivers	Geographic separation, caregiver burnout, limited illness understanding, stigma, financial strain, interpersonal conflict, caregiver health problems, cultural differences in mental illness conceptualization	Reduced treatment engagement, increased relapse risk, poorer adherence, limited assistance with daily functioning, greater social isolation	• Family psychoeducation • Multifamily group therapy • Caregiver skills training • Peer-led family support groups • Respite services • Community-based case management and supported housing	• Hahlweg and Baucom[94] • Claxton et al[95]
	Adverse treatment effects	Negative health outcomes resulting from pharmacologic or other therapeutic interventions for schizophrenia	Medication type/dose, polypharmacy, individual vulnerability, comorbidities, inadequate monitoring or management	Reduced adherence and engagement; direct impairment of physical health and function; exacerbation of stigma; increased morbidity and mortality	• Shared decision-making in medication selection • Regular monitoring and early intervention • Dose optimization • Long-acting injectable use when appropriate • Lifestyle interventions • Pharmacologic management of side effects • Integrated medical and psychiatric care	• Dibonaventura et al[101] • Tandon et al[102] • Huhn et al[105] • Citrome et al[107]

Abbreviations: AUD=alcohol use disorder, CBT = cognitive behavioral therapy, CRT = cognitive remediation therapy, IPS = Individual Placement and Support, SUD=substance use disorder.

METHODS

In June 2025, a multidisciplinary panel was convened to evaluate key drivers of functional impairment in persons with schizophrenia, encompassing psychopathological, individual, societal, and treatment-related factors. The panel was chaired by Rajiv Tandon, MD. Panelists included Deanna M. Barch, PhD; Robert W. Buchanan, MD; Michael F. Green, PhD; Matcheri S. Keshavan, MD; Stephen R. Marder, MD; Henry A. Nasrallah, MD; and Antonio Vita, MD, PhD.

The panel met virtually in a structured, facilitated discussion designed to balance review of the published evidence with expert interpretation and clinical experience. Panelists considered determinants of functional outcome across psychopathological, individual, societal, and treatment-related domains and discussed how these factors interact over the illness course. In addition to analyzing publicly available clinical trial and meta-analytic data, panelists shared their own perspectives on the utility, mechanisms of action, and implementation barriers of psychosocial and psychotherapeutic interventions.

The agenda included (1) identification and categorization of drivers of functional impairment; (2) review of psychosocial interventions; (3) evaluation of validated tools and measurement-based care strategies; and (4) consideration of emerging digital interventions and their potential to enhance scalability.

Consensus was reached through iterative discussion, with a focus on aligning evidence with real-world practice and on generating practical, patient-centered recommendations. This Academic Highlights presents the consensus findings of the panel and is based on review of published literature and clinical experience; it is not intended to represent a systematic review or meta-analysis.

Consensus Statement #1

"Functional outcomes in schizophrenia remain far below what is achievable due to systemic underutilization of evidence-based psychosocial interventions. Despite their demonstrated impact, these tools are often inaccessible, unsupported, or overlooked, reinforcing a culture of therapeutic nihilism."

DRIVERS OF FUNCTIONAL IMPAIRMENT IN SCHIZOPHRENIA

Understanding the drivers of functional impairment in schizophrenia is essential for guiding pharmacological and psychosocial strategies. Based on faculty feedback and panel consensus, these drivers can be grouped into 4 core categories reflecting factors intrinsic to the disorder and its consequences: intrinsic, behavioral, comorbid/consequential, and societal/contextual. Treatment-related factors and systemic barriers, while important contributors to functional outcomes, were distinguished as separate because they do not arise from the underlying pathophysiology of schizophrenia itself (**Table 1**).

Intrinsic drivers arise from core illness features, such as positive and negative symptoms, cognitive deficits, and diminished insight; internalized- or self-stigma is included here as well. Behavioral drivers reflect behaviors that interfere with functioning, including nonadherence to medication or appointments and co-occurring substance or alcohol use disorders. Comorbid and consequential drivers include conditions that frequently co-occur with or result from schizophrenia, such as depressive symptoms and physical comorbidities, defeatist beliefs, and loneliness or social isolation. Societal and contextual drivers encompass environmental and systemic factors, including external stigma/discrimination, poverty, and other adverse social determinants of health. Finally, treatment-related drivers stem from the care process itself, such as medication adverse effects and the complexity or burden of treatment regimens. These domains often interact; for example, cognitive impairment (intrinsic) can hinder social participation, fostering isolation (comorbid/consequential), which in turn exacerbates symptoms and reduces functioning.[21,22] Likewise, discrimination in employment (societal/contextual) can worsen financial instability, increasing stress and undermining illness self-management (intrinsic).[23]

The section that follows addresses each of these domains in turn, highlighting their contribution to functional impairment and opportunities for intervention. This section provides a framework for understanding these drivers, which will be linked in subsequent sections to evidence-based interventions and practical guidance for integrating them into individualized, measurement-based care plans.[18,24]

Intrinsic Drivers of Functional Impairment

Intrinsic drivers stem from the illness itself and include the hallmark symptom domains of schizophrenia: positive, negative, and cognitive symptoms, as well as diminished insight. These features directly impair motivation, learning, decision-making, and social functioning, and often persist even when psychosis is well controlled. Because they are core illness features, intrinsic drivers represent some of the most persistent barriers to functional recovery.

Symptoms. While positive symptoms can significantly impact the daily functioning of the person with schizophrenia and their caregivers,[25] and have negative impact on employment,[23] negative symptoms are considered the larger driver of impairment in schizophrenia.[7,8] Negative symptoms comprise a heterogeneous set of conditions with diverse etiologies, often requiring distinct treatment strategies.[26] Five core domains of negative symptoms are recognized: blunted affect (reduced emotional expression), alogia (limited speech), asociality (reduced social interaction), anhedonia (diminished capacity for pleasure), and avolition (reduced motivation or goal-directed behavior).[27]

Negative symptoms impose a substantial burden on individuals, caregivers, and society, contributing to poor functional outcomes, increased unemployment, greater illness severity, and often higher antipsychotic dosages.[27] There are substantial correlations among these 5 domains, with factor-analytic studies grouping the 5 classic negative symptoms into 2 domains, the first consisting of diminished emotional expression and including blunted affect and alogia and the second consisting of reduced motivation and pleasure and including avolition, anhedonia, and asociality.[7,8,28]

Cognitive impairment. Cognitive impairment is a core feature of schizophrenia, affecting most individuals with the disorder and often emerging during the prodrome before the onset of psychosis.[24,29] Cognitive impairments are seen in both non-social cognition (eg, processing speed, attention, learning and memory, problem-solving, working memory) and social cognition (eg, emotion processing, social perception, attributional bias, mentalizing).[30] These deficits are among the strongest predictors of poor functional outcomes, adversely affecting occupational performance, social relationships, and independent living skills.[30] Meta-analyses show that cognitive deficits in schizophrenia are moderate to large in magnitude compared with healthy controls and are an enduring feature across the across the lifespan of the disorder, even when positive symptoms remit.[31–33]

These impairments stem from a combination of neurodevelopmental and neurodegenerative processes and illness-related factors such as untreated psychosis, anticholinergic burden, and comorbidities, such as depression and substance use.[34–37] Functionally, cognitive deficits limit the acquisition and application of new skills, impair social problem-solving, and reduce the ability to adapt to environmental demands, thereby restricting success in employment, education, independent living, and social integration and collectively limiting an individual's functional recovery.[35,36]

Diminished insight. Diminished insight is a prevalent and clinically significant driver of functional impairment in schizophrenia.[38] It encompasses an impaired awareness of having an illness, misunderstanding of the need for treatment, and/or underestimation of symptom severity. Estimates suggest that poor insight occurs in approximately 50%–98% of individuals with schizophrenia, dependent on the stage of the illness, and is relatively independent of positive symptom remission.[39–41]

The origins of diminished insight are multifactorial, involving illness-related cognitive deficits, particularly in executive function and self-monitoring, negative symptom burden, and possible neurobiological changes affecting self-reflective processes.[41–43]

Functionally, diminished insight is linked to poorer adherence to pharmacological and psychosocial interventions, higher rates of relapse and hospitalization, and reduced engagement with rehabilitation services.

Behavioral Drivers of Functional Impairment

Behavioral drivers reflect actions and habits of people with schizophrenia that undermine recovery, most prominently nonadherence to treatment and substance or alcohol misuse. These behaviors can destabilize symptom control, increase relapse risk, and compound functional impairments. Addressing behavioral drivers often requires tailored interventions to improve treatment engagement and reduce the impact of co-occurring substance use disorders.

Lack of adherence (to medication and appointments). Nonadherence to prescribed pharmacological or psychosocial treatments is a major treatment-related driver of functional impairment in schizophrenia, with rates estimated at 40%–60% in community samples.[44–47] Adherence challenges can be partial or complete and often fluctuate over time. Contributing factors include diminished insight, adverse treatment effects, cognitive impairment, substance use, stigma, and logistical barriers, such as transportation, cost, and lack of family or caregiver support.[45–47]

The consequences of nonadherence are substantial and can lead to increased relapse risk, more frequent hospitalizations, worsening of positive and negative symptoms, higher healthcare costs, and reduced likelihood of functional recovery. Repeated relapses can lead to progressive functional decline, greater treatment resistance, and erosion of social and occupational skills.[48,49]

Alcohol and substance use disorder. Alcohol and substance use disorders (AUDs/SUDs) are highly prevalent in individuals with schizophrenia, with lifetime comorbidity estimates ranging from 40%–60%.[50–54] Commonly misused substances include alcohol, cannabis, stimulants, and nicotine, with cannabis use disorder showing a particularly strong association with earlier illness onset, more severe positive symptoms, and increased risk of relapse.[55–57] The relationship between schizophrenia and SUD is bidirectional: substance use can exacerbate psychotic symptoms and functional decline, while illness-related factors, such as social isolation, impaired coping skills, and diminished insight, can increase vulnerability to substance misuse. Neurobiological factors, including dysregulation of reward system, may also contribute to this comorbidity.[54,58,59]

Functionally, AUDs/SUDs compound the burden of schizophrenia by impairing treatment adherence, increasing risk for hospitalization and homelessness, worsening cognitive and negative symptoms, and contributing to legal, interpersonal, and occupational problems. Substance use may also diminish the effectiveness of psychosocial interventions and reduce the likelihood of recovery-oriented goal attainment.[58,59]

Comorbid/Consequential Drivers of Functional Impairment

Comorbid and consequential drivers include psychiatric and medical conditions that co-occur with schizophrenia or emerge as sequelae of illness. Common examples are depressive symptoms, defeatist beliefs, loneliness, and social isolation, which add an additional burden to already impaired functioning. These conditions frequently interact with intrinsic symptoms, amplifying disability and complicating recovery trajectories.

Depressive symptoms and defeatist beliefs. Depressive symptoms frequently accompany various phases of schizophrenia and may resemble the negative symptoms of the disorder, with prevalence estimates ranging from 25%–50% during the course of illness.[60–62] They may emerge during acute psychotic episodes or in the post-psychotic recovery phase, or persist as part of a chronic affective comorbidity.[63] These symptoms include low mood, hopelessness, anhedonia, guilt, and suicidal ideation and are often intertwined with defeatist beliefs, such as negative self-schemas characterized by low self-worth, perceived incompetence, and pessimism about the future. Such beliefs can be reinforced by the illness experience itself, societal stigma, and repeated functional setbacks.[64–66]

Functionally, depressive symptoms and defeatist beliefs can undermine motivation, goal setting, and engagement with both pharmacological and psychosocial interventions.[65,66] They are associated with poorer social and occupational outcomes, increased relapse risk, and higher suicide rates. Moreover, they can interact with other drivers of impairment, such as cognitive deficits and stigma, creating a reinforcing cycle of loneliness and social isolation.

Consensus Statement #2

"Functional impairment in schizophrenia arises from a constellation of intrinsic and behavioral, comorbid/consequential, societal/contextual drivers, and adverse treatment effects. These include neurocognitive deficits, behavioral and motivational impairments, comorbidities, and social determinants of health. Interventions must be targeted to specific drivers."

Loneliness/social isolation. Loneliness and social isolation are common and debilitating experiences in schizophrenia that are distinct yet interrelated phenomena. Loneliness refers to the subjective distress stemming from a perceived gap between desired and actual social relationships, whereas social isolation describes the objective lack of social contact or network connections.[21] Both are highly prevalent in people with schizophrenia, often beginning early in the illness course, and can persist despite effective management of positive symptoms.[67,68] Qualitative research in early psychosis supports these findings and indicates that loneliness is frequently experienced although clinicians do not tend to explicitly inquire about it.[69]

Contributors to loneliness and social isolation include negative symptoms, such as avolition and asociality (ie, reduced social motivation), cognitive and social cognitive deficits, internal stigma, and functional setbacks that limit opportunities for meaningful interaction.[70,71] Social isolation can be reinforced by socioeconomic disadvantage, housing instability, and limited access to community-based supports. The resulting lack of social engagement not only diminishes quality of life but also predicts poorer functional outcomes, increased depressive symptoms, higher relapse risk, and elevated mortality.[70,72]

Internalized stigma. Stigma remains a pervasive driver of functional impairment in schizophrenia, influencing both how individuals view themselves or internalize negative societal views about their group, ie, all individuals with schizophrenia (internalized- or self-stigma) and how they are perceived and treated by others (public or external stigma will be discussed under "Discrimination/external stigma").[73–75] Self-stigma involves the internalization of negative societal stereotypes, leading to diminished self-esteem, reduced hope, and reluctance to pursue personal or professional goals.[74–76] Internalized stigma has been consistently associated with poorer adherence to treatment, reduced self-efficacy and occupational competence, and lower subjective quality of life and social functioning. It can also exacerbate cognitive dysfunction and limit insight into the disorder.[76–80]

Societal/Contextual Drivers of Functional Impairment

Societal and contextual drivers encompass interpersonal and environmental influences that shape opportunities for recovery. These include the presence or absence of supportive family or caregiver relationships, as well as external pressures, such as stigma, discrimination, poverty, and other adverse social determinants of health. By constraining opportunities for social integration and reinforcing illness-related challenges, these drivers often magnify the impact of intrinsic, behavioral, and comorbid factors.

Discrimination/external stigma. As noted previously, stigma remains a pervasive driver of functional impairment in schizophrenia. *Public* or *external stigma* relates to how individuals with schizophrenia are perceived and treated by others or society.[73–75] Public stigma encompasses discriminatory attitudes and behaviors from employers, healthcare providers, community members, and even family, which can limit opportunities for employment, housing, education, and social participation.[73]

The effects of stigma are compounded by structural barriers, such as policies and institutional practices that disadvantage individuals with serious mental illness.[81,82] Together, these forces can create a self-reinforcing cycle in which stigma limits participation, reduced participation fuels isolation, and isolation further entrenches both self- and public stigma.[83,84]

Social determinants of health. Social determinants of health (SDOH), the non-medical conditions in which people are born, grow, live, work, and age, exert a profound influence on outcomes for individuals with schizophrenia. Adverse SDOH such as poverty, unstable housing, limited educational opportunities, unsafe neighborhoods, food insecurity, and inadequate access to health care interact with illness-related impairments to hinder recovery.[83] These factors reduce opportunities for treatment engagement, increase symptom burden, and constrain functional capacity.[84–89]

The effects of SDOH are cumulative and often mutually reinforcing. Housing instability disrupts continuity of care and medication adherence; unreliable transportation limits access to appointments, employment, and community supports; and low health literacy impairs the ability to navigate complex healthcare systems. For many individuals, particularly those in marginalized or under-resourced communities, structural racism, discrimination, and lack of culturally responsive care further compound these disadvantages.[84,89,90]

Within this broader framework, socioeconomic status represents a central and cross-cutting determinant. The financial and socioeconomic consequences of schizophrenia are substantial and extend beyond the individual to families and communities.[3] People with schizophrenia experience disproportionately high rates of unemployment, poverty, and housing instability, reflecting the combined impact of limited educational attainment, workplace discrimination, and the episodic or chronic nature of the illness on vocational and academic trajectories. Low income and lack of affordable housing contribute to markedly elevated rates of homelessness.[3,89]

Socioeconomic disadvantage both results from and exacerbates illness-related impairments. Individuals with schizophrenia are significantly more likely to live in poverty than those without psychotic disorders, a disparity associated with more severe positive, negative, and cognitive symptoms and greater risk for suicidal behavior. Poverty restricts access to nutritious food, safe and stable housing, and transportation, while financial stress contributes to worsening psychiatric symptoms and reduced treatment adherence. At the systems level, the socioeconomic burden is reflected in high healthcare utilization, reliance on disability benefits, and lost productivity.[90–92]

Lack of family or caregiver support. Family and caregiver support is a critical extrinsic factor influencing recovery in schizophrenia. When present, it can facilitate treatment adherence, provide emotional and practical assistance, and create an environment that supports rehabilitation. Conversely, the absence of such support, or the presence of strained, conflict-laden, or overinvolved relationships, can hinder engagement with services, increase relapse risk, and exacerbate functional impairments.[93–95]

Contributors to insufficient family or caregiver support include geographic separation, caregiver burnout, limited

understanding of schizophrenia, stigma, financial strain, and breakdowns in family relationships.[94,96] In some cases, caregivers may themselves face health or mental health challenges, limiting their capacity to provide consistent help.[97,98] Cultural differences in conceptualizing mental illness and recovery can also affect the type and quality of support offered.[93,97,99]

Treatment-Related Burden

Treatment-related drivers arise from the therapeutic process itself. Adverse effects of medications, anticholinergic burden, and the complexity of treatment regimens can diminish quality of life and create new functional barriers. If not managed proactively, these drivers can erode adherence and counteract the benefits of symptom control, limiting progress toward recovery.

Adverse effects from antipsychotic and adjunctive medications are a significant treatment-related driver of functional impairment in schizophrenia.[45,100–102] These can include extrapyramidal symptoms, tardive dyskinesia, akathisia, sedation, weight gain, metabolic syndrome, hyperprolactinemia, and anticholinergic burden.[103–107] Even when clinically manageable, these effects may reduce treatment satisfaction and adherence, impacting long-term symptom control and functional outcomes.[108,109]

The burden of side effects is shaped by several factors, such as medication type and dose, polypharmacy, individual susceptibility, and comorbid health conditions.[110] Adverse effects can directly impair physical health, limit participation in work or social activities, and exacerbate stigma, particularly when visible symptoms (eg, tremor, weight changes) occur.[103,104] Some side effects, such as metabolic complications, also contribute to elevated cardiovascular and all-cause mortality in this population.[103]

Systemic Barriers

Systemic barriers operate at the level of health care structures and social policy, shaping the environment in which recovery occurs. Limited access to appropriate care, lack of vocational rehabilitation resources, and disincentives linked to disability payments can constrain opportunities for functional improvement. These challenges often interact with other drivers resulting in reduced treatment engagement, limiting community participation, and reinforcing functional disability.[93]

Access to care: Inadequate access to quality mental healthcare, particularly early intervention programs, can impede recovery and worsen disability.[93]

Vocational support: a lack of effective vocational training and employment support programs limits opportunities for people with schizophrenia to find and maintain competitive employment.[111]

Disability benefits: while disability benefits provide crucial support, the structure of some benefit systems may create disincentives to seeking employment due to the link between benefits and health insurance.[112]

Consensus Statement #3

"A range of psychosocial interventions, including cognitive behavioral therapy, cognitive remediation, social skills training, supported employment, and family-focused therapy, are effective in improving functional outcomes across multiple domains. However, their deployment remains inconsistent and often inadequate."

EVIDENCE-BASED PSYCHOSOCIAL INTERVENTIONS

While pharmacotherapy remains central to managing schizophrenia, it is insufficient on its own to achieve full functional recovery. Evidence-based psychosocial interventions provide complementary strategies that directly target the cognitive, behavioral, emotional, and social processes underlying disability in schizophrenia. These interventions employ structured, manualized approaches designed to reduce symptom burden, enhance adaptive skills, improve social and occupational functioning, and promote overall recovery.

In the section that follows, we review the evidence for key psychosocial and psychotherapeutic interventions. Each subsection highlights the mechanisms of action and strength of evidence for the intervention reviewed as well as key references for additional reading. Because the clinical considerations for implementation are largely consistent across approaches, they are presented collectively in a separate section that follows, rather than repeated within each intervention.

Cognitive Behavioral Therapy

Therapeutic target. Cognitive behavioral therapy (CBT) is a structured, time-limited, and goal-directed intervention that seeks to reduce distress and disability by identifying and modifying maladaptive beliefs and behaviors. In schizophrenia, CBT for psychosis (CBTp) targets positive symptoms, such as hallucinations and delusions, negative symptoms, and functional impairments, by fostering adaptive coping strategies, reality testing, and problem-solving skills. CBT also works to enhance self-efficacy, reduce self-stigma, and improve engagement with treatment and daily activities.[18]

Evidence. CBT is among the most extensively studied psychosocial interventions for schizophrenia. The American Psychiatric Association (APA) Schizophrenia Guideline (2020), the National Institute for Health and Care Excellence (NICE) guideline (UK), and the European Psychiatric Association (EPA) all recommend CBT as part of a comprehensive treatment plan, particularly for individuals with persistent positive symptoms despite antipsychotic therapy.[13,113,114] Meta-analyses and large randomized controlled trials demonstrate that CBT produces modest but significant improvements

in psychotic symptoms, depression, and functioning, particularly in people with schizophrenia with persistent symptoms despite antipsychotic treatment.[115] An umbrella review of meta-analyses confirms small-to-medium effects on general and positive symptoms at end of treatment (**Table 2**).[116] Additionally, CBTp has demonstrated evidence for relapse prevention as part of a broader treatment plan.[117] Effects on functioning are generally smaller than for symptom reduction; however, the consistency of findings across trials supports CBT as a valuable adjunctive intervention.[118]

Cognitive Remediation (Including Social Cognitive Training)

Therapeutic target. Cognitive remediation (CR) is a structured, behavioral intervention designed to improve neurocognitive processes, such as attention, memory, and executive function, with downstream benefits for daily functioning.[119] Training typically involves repeated, targeted practice of cognitive tasks that are adapted in their difficulty level, often supported by strategy coaching and real-world application. Social cognitive training is a related approach that targets social cognitive domains, such as emotion recognition, theory of mind, and attributional style, abilities that are strongly linked to social functioning in schizophrenia.[119,120]

Evidence. CR is one of the most extensively studied psychosocial interventions in schizophrenia, with more than 50 randomized controlled trials. The EPA explicitly recommends CR,[114] particularly when combined with psychosocial rehabilitation, to improve functional outcomes. The APA Schizophrenia Guideline also acknowledges CR as a beneficial adjunctive intervention.[121]

A large body of randomized controlled trials and meta-analyses demonstrates that CR produces moderate improvements in global cognition, with downstream effects on psychosocial functioning and community outcomes.[119,122,123] Gains are most robust when CR is combined with rehabilitation supports, such as vocational training or psychosocial rehabilitation.[124] Social cognitive training also shows significant benefits, particularly in emotion recognition and theory of mind, which sometimes translate into improved social competence and interpersonal outcomes.[120] More recent meta-analyses indicate that these improvements may extend beyond test performance to real-world functional domains, including employment, social relationships, and independent living.[125]

The most comprehensive and methodologically rigorous meta-analysis to date synthesized 130 randomized controlled trials including 8851 participants and confirmed small-to-moderate effects on both global cognition (d = 0.29) and functioning (d = 0.22). Importantly, the presence of an active therapist, structured development of cognitive strategies, and integration with psychosocial rehabilitation significantly enhanced outcomes. Patients with lower education, lower premorbid IQ, and greater baseline symptom severity derived particular benefit, underscoring the broad applicability of CR across illness stages.[126]

Optimal delivery involves repeated, structured practice (eg, 2–3 sessions per week for several months) with therapist support to promote generalization of skills into daily life.[127] Combining CR with supported employment, social skills training, or other rehabilitation programs maximizes transfer to functional outcomes.[124] For greatest impact, CR should be embedded within comprehensive treatment plans, tailored to individual cognitive profiles, and explicitly linked to functional rehabilitation goals.[127]

Motivational Interviewing

Therapeutic target. Motivational interviewing (MI) is a collaborative, person-centered counseling style that helps individuals resolve ambivalence about change and enhance intrinsic motivation. In schizophrenia, MI is most often applied to improve treatment adherence and address co-occurring substance use disorders. By emphasizing empathy, reflective listening, and empowerment, MI facilitates engagement, builds therapeutic alliance, and promotes goal-directed behavior change.[128]

Evidence. Systematic reviews and meta-analyses indicate that MI is effective in improving medication adherence and reducing substance abuse among individuals with schizophrenia and other serious mental illnesses. In medication adherence studies, MI has been associated with improved insight, stronger alliance with providers, and increased continuation of treatment.[129–132] When combined with psychoeducation or cognitive-behavioral strategies, MI demonstrates additional benefits for improving negative symptoms.[133] While effect sizes are modest, MI has shown consistent utility as an engagement- and adherence-enhancing intervention.[130] To date, no major psychiatric or neurological professional society has formally endorsed MI specifically for improving functional outcomes, although MI is commonly referenced in behavioral health and implementation toolkits as an evidence-based method to support engagement, adherence, and readiness to change.

Psychoeducation

Therapeutic target. Psychoeducation seeks to improve illness understanding and self-management skills for people with schizophrenia and their families. By providing structured information on the nature of schizophrenia, treatment options, early warning signs of relapse, and coping strategies, psychoeducation empowers patients and caregivers to take an active role in care. This increases adherence, reduces stress and expressed emotion in families, and builds the foundation for more effective engagement in rehabilitation.[134]

Evidence. Psychoeducation is one of the most consistently supported psychosocial interventions in schizophrenia. The APA, the EPA, and the World

Federation of Societies of Biological Psychiatry all recommend structured psychoeducation for patients and families as part of standard treatment.[114,121,135] The NICE schizophrenia guideline (UK) similarly endorses family intervention incorporating psychoeducation.[136]

Beyond guideline endorsements, multiple meta-analyses show that psychoeducation reliably reduces relapse and rehospitalization rates with moderate effect while improving medication adherence and functional outcomes, including social and occupational functioning.[137–139] These benefits are robust across delivery formats (individual, group, or family-based) and across cultural contexts, with medium effect sizes (**Table 2**).

Social Skills Training

Therapeutic target. Social skills training (SST) uses behavioral techniques such as modeling, role-play, feedback, and reinforcement to teach concrete interpersonal and daily living skills. The goal is to improve communication, assertiveness, problem-solving, and community functioning, thereby reducing disability and enhancing independence.[140]

Evidence. The APA and EPA both endorse SST as an evidence-based psychosocial intervention for schizophrenia, particularly for improving functional outcomes.[114,121] Meta-analyses and systematic reviews consistently demonstrate that SST enhances social functioning, independent living skills, and vocational outcomes, with effect sizes in the small-to-moderate range.[141,142] Evidence also supports combining SST with cognitive remediation or supported employment to maximize generalization to real-world outcomes.

Supported Employment, Education, and Housing

Therapeutic target. Supported housing provides individuals with schizophrenia access to safe, permanent housing with flexible support services. The Housing First model emphasizes immediate access to independent housing without preconditions, such as sobriety or treatment adherence, coupled with mobile clinical support. Stable housing reduces environmental stressors and enables consistent engagement in care, social relationships, and rehabilitation.[143,144]

Supported employment, most commonly delivered through the Individual Placement and Support (IPS) model, helps individuals with schizophrenia obtain and sustain competitive jobs in the open labor market and is endorsed by both the APA and EPA.[114,121] IPS emphasizes rapid job search, matching work to individual preferences, integration with mental health care, and ongoing support without time limits. Employment itself is viewed as a therapeutic tool, fostering self-efficacy, social inclusion, and independence. Emerging evidence demonstrates that supported education, often delivered in parallel with or integrated into IPS, can meaningfully enhance functional recovery for individuals with schizophrenia, particularly younger adults pursuing vocational–academic pathways.[145]

Evidence. The NICE 2020 rehabilitation guideline[146] recommends supported accommodation and housing interventions as key components of long-term recovery for complex psychosis. Large, randomized trials and systematic reviews consistently show that supported housing substantially improves housing stability compared with treatment as usual.[144,147] While direct effects on symptoms are modest, functional and quality-of-life outcomes improve when stable housing is paired with clinical and psychosocial support.

Supported employment is one of the most consistently validated psychosocial interventions in schizophrenia. In addition to APA and EPA endorsement, multiple meta-analyses and large randomized controlled trials show that IPS more than doubles the likelihood of competitive employment compared with traditional vocational rehabilitation, with additional benefits in work tenure, income, and quality of life.[148–150] Importantly, IPS has demonstrated effectiveness across stages of illness, including early psychosis, and across diverse cultural and health system contexts, underscoring its generalizability.

Supported education is likewise supported by systematic reviews which have demonstrated that supported education improves postsecondary enrollment, persistence, and academic achievement, with effect sizes comparable to early IPS interventions.[145] Moreover, guidelines now recognize supported education as an important component of recovery-oriented care, particularly within coordinated specialty care models for early psychosis.[13,114,146]

Family-Focused Interventions

Therapeutic target. Family-focused interventions target the interpersonal environment, aiming to reduce relapse risk and support recovery by modifying patterns of communication, expressed emotion, and problem-solving within the family unit.[151,152] Core components typically include psychoeducation about schizophrenia, structured training in communication and conflict resolution, and strategies for crisis management and relapse prevention.[153,154] By equipping families with skills to manage stress and foster collaborative approaches to care, these interventions create a supportive context that promotes treatment adherence, functional gains, and long-term recovery.[154–156]

Evidence. A robust body of randomized controlled trials and meta-analyses demonstrates that family-focused interventions significantly reduce relapse and rehospitalization rates compared with standard treatment.[117,155,157] A network meta-analysis of 90 trials (n >10,000) found that nearly all family intervention models significantly reduced relapse at 12 months, with family psychoeducation showing the strongest effect (**Table 2**). Other reviews estimate that family interventions

can reduce relapse risk by 50%–60%.[157] Benefits extend beyond symptom reduction, with improvements in medication adherence, functional outcomes, and quality of life and reductions in caregiver burden.[117,155–157] Evidence suggests that structured, multi-session formats are most effective, particularly when initiated early in the illness course.[155,158] Culturally adapted models have also demonstrated effectiveness in improving engagement and outcomes across diverse populations.[156,159] Major guidelines and professional societies endorse family-focused interventions and psychoeducation.[14,121,136]

Mindfulness and Acceptance-Based Therapies

Mechanism of action. Mindfulness-based interventions (MBIs) and acceptance-based approaches (eg, acceptance and commitment therapy [ACT]) aim to change a person's relationship to voices and intrusive thoughts rather than eliminate them. Core processes include present-focused attention, acceptance to reduce experiential avoidance, cognitive defusion/decentering from distressing internal events, and values-guided actions to enhance psychological flexibility. These mechanisms are linked to reductions in distress and improved functioning in psychosis.[160-162] In a mediation analysis using inpatient ACT data, reduced believability of hallucinations (defusion) explained decreases in hallucination-related distress, supporting a mechanism of "changing the relation to symptoms."[163]

Evidence. Meta-analyses and systematic reviews in schizophrenia-spectrum samples show small-to-moderate improvements in total and positive symptoms, mood, negative symptoms, and functioning and (in some analyses) reduced hospitalization when mindfulness/acceptance approaches are added to usual care.[160-162,164] ACT-focused meta-analysis suggests small effects and emphasizes heterogeneity and risk-of-bias considerations, tempering earlier pooled estimates.[165] Representative randomized trials include brief ACT adjuncts for inpatients showing lower rehospitalization at 4 months and short-term gains in affect and hallucination-related distress,[166,167] group Person-Based Cognitive Therapy/mindfulness for distressing voices reducing voice-related distress,[168] and an MBI-psychoeducation program improving symptoms, functioning, insight, and rehospitalization outcomes versus psychoeducation or treatment as usual at 6 months.[169]

Lifestyle Interventions (Physical Activity)

Therapeutic target. Physical exercise promotes neuroplasticity, improves cardiovascular and metabolic health, and reduces inflammation and oxidative stress, factors implicated in the pathophysiology of schizophrenia. Exercise also enhances the release of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), which supports synaptic plasticity and cognitive function.[170,171] Structural brain benefits, such as increased hippocampal volume and white matter integrity, have also been observed.[172] Beyond biological effects, exercise provides behavioral activation, structured daily activity, and opportunities for social engagement, all of which contribute to improved functioning.[171,173]

Evidence. Meta-analyses demonstrate that aerobic and resistance exercise significantly improve cardiorespiratory fitness, negative symptoms, depressive symptoms, cognition, and overall functioning in individuals with schizophrenia.[171,173] One recent meta-analysis found that adjunctive aerobic exercise significantly reduces Positive and Negative Syndrome Scale (PANSS) total scores (MD = −4.84, 95% CI, −5.72 to −3.96), with notable reductions in negative symptoms when conducted for 2–3 months at 100–220 minutes per week.[174] Another review comparing modalities found that aerobic exercise significantly decreased PANSS negative symptom scores, whereas resistance training alone had less impact, and combined training showed mixed results.[175] Additionally, exercise interventions (particularly aerobic) yield small but meaningful improvements in working memory in schizophrenia spectrum disorders.[176] In clinical trials, combining aerobic exercise with computerized cognitive remediation therapy produced stronger improvements in processing speed, cognitive flexibility, negative symptoms, and serum BDNF compared to exercise alone.[177] Exercise alone also increases BDNF levels and shows preliminary cognitive gains, though cognitive benefits may lag behind neurotrophic changes.[178,179]

Consensus Statement #4

"Despite robust evidence of moderate benefit, real-world utilization of psychosocial interventions is limited by access, workforce shortages, inadequate training, and low provider expectations. Addressing these barriers is essential to translating evidence into outcomes. Additionally, each of these psychosocial interventions needs refinements to facilitate individualized application."

IMPLEMENTATION STRATEGIES, FUTURE DIRECTIONS, AND CONCLUSIONS

A practical framework for implementing psychosocial interventions in schizophrenia begins with a structured assessment of the key drivers of functional impairment for the individual patient. These may include negative symptoms, cognitive deficits, diminished insight, depressive symptoms, social disconnection, substance use, or social determinants of health.[180,181] Organizing these domains, as outlined in **Table 1**, helps clinicians identify priority targets for intervention and clarify the mechanisms most likely to support improvement.

Interventions should then be selected and matched to the specific driver(s) identified, guided by the mechanisms

of action summarized in **Table 2**. Additionally, efficiencies can often be achieved by combining complementary interventions, as certain approaches are particularly effective when delivered together. For example, cognitive remediation is most appropriate for patients with prominent cognitive deficits and is particularly effective when paired with supported employment, a combination shown to enhance generalization of cognitive gains and produce meaningful improvements in vocational functioning.[182,183] Similarly, social skills training may be complemented by social cognition interventions to strengthen both the perceptual and behavioral components of social interaction.[120,184] Psychoeducation may be reinforced through family-focused interventions, which extend skill-building to the caregiving environment and improve communication, engagement, and relapse prevention.[137,185] Motivational interviewing can be integrated with adherence-focused interventions to improve engagement and reduce disengagement risk in schizophrenia[186] and can also be used adjunctively with cognitive-behavioral therapies to strengthen motivation and treatment commitment.[187] Even lifestyle interventions, including structured exercise, may be layered onto other psychosocial approaches to improve energy, reduce depressive symptoms, and support overall functional capacity.[171] Incorporating these evidence-based combinations enhances efficiency, allows interventions to reinforce one another, and better addresses the multifaceted challenges that contribute to functional impairment.

Successful implementation also requires grounding treatment in each patient's priorities, such as returning to work or school, maintaining independent living, or improving social connection.[188] Shared decision-making ensures that selected interventions are feasible, personally meaningful, and more likely to be sustained. Anchoring interventions in patient-defined functional goals also creates a natural structure for measurement, review, and iterative refinement (**Figure 2**).

Routine, measurement-based assessment is central to this framework. Validated functional outcome measures, including the Multnomah Community Ability Scale, Social and Occupational Functioning Assessment Scale, Personal and Social Performance scale, and WHO Disability Assessment Schedule (WHODAS) 2.0, offer reliable ways to track change over time.[189–192] Embedding these measures into electronic medical records or collecting them via patient-reported digital platforms facilitates integration into routine workflows, supports collaborative review, and strengthens communication across the treatment team. Regular reassessment allows clinicians to determine whether interventions, alone or in combination, are producing the intended functional gains and to identify early signs of stagnation, skill plateau, or new barriers.

The framework is designed to support a flexible, iterative approach within a stepped-care model. Patients may begin with lower-intensity or more scalable interventions

Figure 2.
A Practical Framework for Implementation and Refinement of Psychosocial Services for Patients With Schizophrenia



Abbreviations: ACT=acceptance and commitment therapy, CBTp=cognitive behavioral therapy for psychosis, CR=cognitive remediation, MBI=mindfulness-based intervention, MCAS=Multnomah Community Ability Scale, MI=motivational interviewing, SOFAS=Social and Occupational Functioning Assessment Scale, SST=social skills training, WHODAS=WHO Disability Assessment Schedule.

Table 2.

Evidence-Based Psychosocial Interventions

Intervention	Primary targets	Mechanism(s) of action	Strength of evidence	Key implementation considerations	Effect size/objective metrics	Key references
Cognitive behavioral therapy for psychosis	Positive and negative symptoms, functional impairments, self-stigma	Modifies maladaptive thoughts/behaviors, enhances coping strategies, reduces distress associated with symptoms	High (multiple RCTs, meta-analyses)	Requires trained therapists; may need adaptation for cognitive deficits	Relapse prevention OR ≈0.45 Symptom reduction SMD 0.2–0.4	• Berendsen et al[116] • Bighelli et al[117]
Cognitive remediation (CR) (including social cognitive training [SCT])	Neurocognitive processes, eg, attention, memory, executive function	CR: improves neurocognitive skills (eg, memory, attention, executive function) through structured exercises SCT: improves recognition of emotions, theory of mind, and social perception	High	Often combined with skills training; adherence and engagement critical	Global cognition: Hedges g=0.19–0.33; functioning: g=0.21	• Lejeune et al[119] • Vita et al[126]
Motivational interviewing	Treatment adherence, substance use disorder. Improved disease insight. Some efficacy for positive and negative symptom improvement[130]	Enhances intrinsic motivation to engage in treatment and recovery-oriented activities	Moderate (fewer RCTs; meta-analyses)	Often adjunctive; may improve adherence and readiness for change	Improved adherence, fewer rehospitalizations; g=0.15–0.17	• Lu et al[129] • Chien et al[131] • Wang et al[132]
Psychoeducation	Treatment adherence, relapse prevention, coping strategies	Improves illness knowledge, insight, and self-management; can involve family	High	Can be delivered individually or in groups; scalability with digital platforms	Relapse OR 0.63 at 12 mo; medium effect for relapse ≤12 mo	• Bighelli et al[117] • Xia et al[138] • Zhao et al[139]
Social skills training	Improves communication and problem solving; reduces disability and enhances independence	Builds communication, interpersonal, and community-living skills	High	Best when integrated into community settings; booster sessions may be needed	Negative symptoms g=0.20–0.30; psychopathology g=0.30–0.40	• Turner et al[141] • Solmi et al[142]
Supported employment (eg, IPS)	Enhances independence, job satisfaction, and tenure	Rapid job placement with ongoing support; fosters vocational integration	High	Fidelity to IPS model predicts outcomes; funding and policy barriers common	Competitive employment: RR=1.63 (95% CI, 1.46–1.82); Job tenure: d=0.55 (95% CI, 0.33–0.79); job length: d=0.46	• Frederick and VanderWeele 2019[149] • Modini et al[150]
Supported housing	Enhances independence, reduces environmental stressors	Provides stable living environment to support recovery	High	Requires coordination with community resources; availability varies by region	Housing stability large ↑; QoL mixed	• Stergiopoulos et al[143] • Aubry et al[144]
Family-focused interventions	Enhances family communication, problem-solving, and support; reduces relapse	Psychoeducation about schizophrenia, structured training in communication and conflict resolution, and strategies for crisis management and relapse	High	Requires family engagement; culturally sensitive approaches needed	Relapse OR 0.35; psychoeducation OR 0.18; relapse risk ↓50%–60%	• Bighelli et al[117] • Rodolico et al[157]
Mindfulness and acceptance-based therapy	Positive symptoms	Aim is to change a person's relationship to voices and hallucinations rather eliminate them	Moderate	Requires specially trained therapists; sessions should be shorter and adapted for psychosis (structured guidance, concrete metaphors). Best used as an adjunct to standard care; engagement can be improved through group delivery and peer support	Overall symptoms: g = –0.80 (95% CI, –1.31 to –0.29) Negative symptoms: g = –0.24 (95% CI, –0.44 to –0.03)	• Jansen et al[160] • Louise et al[161]
Lifestyle interventions (exercise)	Promotes neuroplasticity, improves cardiovascular and metabolic health	Improves physical health, reduces medication side effects, enhances mood	Moderate	Requires ongoing support; may be integrated into group programs	PANSS total: MD = −4.84 (95% CI, −5.72 to −3.96); PANSS negative symptom subscale (MD = –2.11; 95% CI, –3.26 to –0.95) and SANS (MD = -9.11; 95% CI, –11.94 to –6.27)	• Firth et al[171] • Guo et al[174]

Abbreviations: IPS=Individual Placement and Support, MD=mean difference, OR=odds ratio, PANSS=Positive and Negative Syndrome Scale, QoL=quality of life, RCT=randomized controlled trial, RR=relative risk, SANS=Scale for the Assessment of Negative Symptoms, SMD=standardized mean difference.

(eg, group psychoeducation, brief CBTp), with escalation to more intensive or multimodal strategies if progress is limited.[124,181] Measurement-based feedback guides the timing and selection of these adjustments, ensuring that treatment plans remain dynamic and responsive to the evolving needs, goals, and stage of illness of each patient. When progress is slow, combining interventions, rather than simply increasing intensity, may offer the greatest advantage by targeting complementary mechanisms and addressing multiple drivers simultaneously.

Pharmacotherapy remains essential in comprehensive care, yet no medications are approved for negative symptoms or cognitive impairment. At the same time, emerging digital therapeutics offer scalable, evidence-based strategies to augment psychosocial care. The recent CONVOKE trial (NCT05838625) in which the digital therapeutic CT-155 significantly improved experiential negative symptoms as measured by the Motivation and Pleasure subscale of the Clinical Assessment Interview for Negative Symptoms exemplifies the potential of these innovations.[193] Importantly, such technologies should be understood as tools that extend reach and sustainability rather than as replacements for psychosocial care.

The consensus panel concludes that effective psychosocial interventions are well established but remain underutilized, not because of uncertain efficacy but due to systemic, financial, and cultural barriers. Randomized controlled trials and meta-analyses consistently show improvements in symptoms, cognition, functional capacity, and quality of life across multiple modalities, yet translation into practice is limited. A practical framework for progress begins with systematic assessment of the drivers of functional impairment and aligning interventions accordingly, supported by validated outcome measures and iterative, patient-centered treatment adjustments (**Table 2**, **Figure 2**).

Taken together, the evidence supports a clear mandate: to close the gap between research and practice, care must be grounded in patient priorities, informed by validated measurement, and delivered through recovery-oriented, multimodal, and digitally enabled strategies. By doing so, clinicians can help shift the field from a narrow focus on symptom control toward a paradigm of meaningful functional recovery.

FINANCIAL DISCLOSURES

All authors received an honorarium from Boehringer-Ingelheim Pharmaceuticals, Inc., for participation in the panel meeting.

Dr Tandon has received an unrestricted educational grant from Boehringer-Ingelheim. **Dr Buchanan** has received advisory board fees from Acadia, Karuna, Merck, and Neurocrine. **Dr Keshavan** has received consulting fees from Alkermes and Bristol-Myers Squibb. **Dr Marder** has received consulting fees from Boehringer-Ingelheim, Otsuka, Merck, Sunovion, Karuna, Neurocrine, and Newron and grant/research support from Boehringer-Ingelheim. **Dr Nasrallah** has received consulting fees from Boehringer-Ingelheim, Bristol-Myers Squibb, Janssen, Karuna, and Cerevel; honoraria for speaking/teaching from Abbvie, Alkermes, Acadia, Axsome, Intra-Cellular, Janssen, Neurocrine, Otsuka, Vanda, and Teva; and advisory board fees from Boehringer-Ingelheim. **Drs Barch**, **Green**, and **Vita** report no other relevant financial relationships.

REFERENCES

1. GBD 2021 Diseases and Injuries Collaborators *Lancet*. May 18 2024;403(10440):2133–2161.
2. Solmi M, Seitidis G, Mavridis D, et al. *Mol Psychiatry*. Dec 2023;28(12):5319–5327.
3. Lin C, Zhang X, Jin H. *Pharmacoeconomics*. Feb 2023;41(2):139–153.
4. Tandon R, Gaebel W, Barch DM, et al. *Schizophr Res*. Oct 2013;150(1):3–10.
5. American Psychiatric Association. Schizophrenia spectrum and other psychotic disorders. *Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision (DSM-5-TR)*. American Psychiatric Publishing; 2022.
6. Millan MJ, Agid Y, Brune M, et al. *Nat Rev Drug Discov*. Feb 1 2012;11(2):141–68.
7. Barch DM, Bustillo J, Gaebel W, et al. *Schizophr Res*. Oct 2013;150(1):15–20.
8. Govil P, Kantrowitz JT. *CNS Drugs*. Mar 2025;39(3):243–262.
9. Tandon R, Nasrallah H, Akbarian S, et al. *Schizophr Res*. Feb 2024;264:1–28.
10. Nasrallah H, Tandon R, Keshavan M. *Epidemiol Psychiatr Sci*. Dec 2011;20(4):317–27.
11. Silva MA, Restrepo D. *Rev Colomb Psiquiatr (Engl Ed)*. Oct-Dec 2019;48(4):252–260.
12. Tandon R, Targum SD, Nasrallah HA, et al. *J Psychiatr Pract*. Nov 2006;12(6):348–63.
13. Keepers GA, Fochtmann LJ, Anzia JM, et al. *Am J Psychiatry*. Sep 1 2020;177(9):868–872.
14. Zhou W, Han H, Xiao X, et al. *Asian J Psychiatr*. Jan 2025;103:104319.
15. Harris A, Boyce P. *Aust N Z J Psychiatry*. Jun 2013;47(6):501–4.
16. Vita A, Barlati S. *Front Psychiatry*. 2019;10:147.
17. Gupta N, Gupta M, Esang M. *Cureus*. May 2023;15(5):e39488.
18. Barlati S, Nibbio G, Vita A. *Curr Opin Psychiatry*. May 1 2024;37(3):131–139.
19. Vita A, Barlati S. *Curr Opin Psychiatry*. May 2018;31(3):246–255.
20. Tandon R, Devellis RF, Han J, et al. *Psychiatry Res*. Sep 15 2005;136(2–3):211–21.
21. Yu B, Sun Z, Li S, et al. *Schizophr Res*. May 2024;267:150–155.
22. Thomas EC, Snethen G, Salzer MS. *Am J Orthopsychiatry*. 2020;90(1):90–97.
23. Marwaha S, Johnson S. *Soc Psychiatry Psychiatr Epidemiol*. May 2004;39(5):337–49.
24. Calzavara-Pinton I, Nibbio G, Barlati S, et al. *Brain Sci*. Aug 6 2024;14(8):791.
25. Ruiz-Castaneda P, Santiago Molina E, Aguirre Loaiza H, et al. *Cogn Res Princ Implic*. Aug 12 2022;7(1):78.
26. Tandon R, DeQuardo JR, Taylor SF, et al. *Schizophr Res*. Oct 27 2000;45(3):191–201.
27. Kirkpatrick B, Fenton WS, Carpenter WT, Jr., et al. *Schizophr Bull*. Apr 2006;32(2):214–9.
28. Blanchard JJ, Cohen AS. *Schizophr Bull*. Apr 2006;32(2):238–45.
29. Howes OD, Fusar-Poli P, Bloomfield M, et al. *Curr Pharm Des*. 2012;18(4):459–65.
30. Green MF, Horan WP, Lee J. *World Psychiatry*. Jun 2019;18(2):146–161.
31. Allott K, Liu P, Proffitt TM, et al. *Schizophr Res*. Feb 2011;125(2–3):221–35.
32. Giuliano AJ, Li H, Mesholam-Gately RI, et al. *Curr Pharm Des*. 2012;18(4):399–415.
33. Szoke A, Trandafir A, Dupont ME, et al. *Br J Psychiatry*. Apr 2008;192(4):248–57.
34. McCutcheon RA, Keefe RSE, McGuire PK. *Mol Psychiatry*. May 2023;28(5):1902–1918.
35. Bowie CR, Harvey PD. *Psychiatr Clin North Am*. Sep 2005;28(3):613–33, 626.
36. Gebreegziabhere Y, Habatmu K, Mihretu A, et al. *Eur Arch Psychiatry Clin Neurosci*. Oct 2022;272(7):1139–1155.
37. Elvevag B, Goldberg TE. *Crit Rev Neurobiol*. 2000;14(1):21.
38. Henriksen MG, Parnas J. *Schizophr Bull*. May 2014;40(3):542–7.
39. Roux P, Faivre N, Urbach M, et al. *Schizophr Res*. Feb 2023;252:48–55.
40. Sakai Y, Ito S, Matsumoto J, et al. *Neuropsychopharmacol Rep*. Sep 2023;43(3):373–381.
41. Keshavan MS, Rabinowitz J, DeSmedt G, et al. *Schizophr Res*. Oct 1 2004;70(2–3):187–94.
42. Osatuke K, Ciesla J, Kasckow JW, et al. *Compr Psychiatry*. Jan-Feb 2008;49(1):70–7.
43. Velligan DI, Sajatovic M, Hatch A, et al. *Patient Prefer Adherence*. 2017;11:449–468.
44. Ramu N, Kolliakou A, Sanyal J, et al. *BMJ Open*. Jun 12 2019;9(6):e028929.
45. Semahegn A, Torpey K, Manu A, et al. *Systematic Reviews*. 2020;9(1):17.
46. Kane JM, Kishimoto T, Correll CU. *World Psychiatry*. Oct 2013;12(3):216–26.
47. Emsley R, Chiliza B, Asmal L, et al. *BMC Psychiatry*. Feb 8 2013;13:50.
48. Harvey PD, Rosenthal JB. *Schizophr Res*. Jun 2018;196:14–21.

49. Strassnig MT, Harvey PD. *CNS Spectr*. Dec 2014;19 Suppl 1:16–23; quiz 13–5, 24.
50. Nesvag R, Knudsen GP, Bakken IJ, et al. *Soc Psychiatry Psychiatr Epidemiol*. Aug 2015;50(8):1267–76.
51. Archibald L, Brunette MF, Wallin DJ, et al. *Alcohol Res*. 2019;40(1):arcr.v40.1.06.
52. Chesney E, Lawn W, McGuire P. *Cannabis Cannabinoid Res*. Feb 2024;9(1):49–58.
53. Hunt GE, Large MM, Cleary M, et al. *Drug Alcohol Depend*. Oct 1 2018;191:234–258.
54. Lambert M, Conus P, Lubman DI, et al. *Acta Psychiatr Scand*. Aug 2005;112(2):141–8.
55. Lahteenvuo M, Luykx JJ, Taipale H, et al. *Br J Psychiatry*. Dec 2022;221(6):758–765.
56. Brunette MF, Mueser KT, Babbin S, et al. *Schizophr Res*. Apr 2018;194:4–12.
57. Hasan A, von Keller R, Friemel CM, et al. *Eur Arch Psychiatry Clin Neurosci*. Jun 2020;270(4):403–412.
58. Khokhar JY, Dwiel LL, Henricks AM, et al. *Schizophr Res*. Apr 2018;194:78–85.
59. Masroor A, Khorochkov A, Prieto J, et al. *Cureus*. Jul 2021;13(7):e16722.
60. Li Z, Xue M, Zhao L, et al. *J Affect Disord*. Nov 1 2021;294:33–38.
61. Krynicki CR, Upthegrove R, Deakin JFW, et al. *Acta Psychiatr Scand*. May 2018;137(5):380–390.
62. Goldman RS, Tandon R, Liberzon I, et al. *Psychopathology*. 1992;25(1):49–56.
63. Siris SG, Addington D, Azorin JM, et al. *Schizophr Res*. Mar 1 2001;47(2–3):185–97.
64. van Rooijen G, Vermeulen JM, Ruhe HG, et al. *CNS Spectr*. Apr 2019;24(2):239–248.
65. Campellone TR, Sanchez AH, Kring AM. *Schizophr Bull*. Nov 2016;42(6):1343–1352.
66. Grant PM, Beck AT. *Schizophr Bull*. Jul 2009;35(4):798–806.
67. Lim MH, Manera KE, Owen KB, et al. *Sci Rep*. Aug 1 2023;13(1):12453.
68. Hajek A, Gyasi RM, Pengpid S, et al. *Epidemiol Psychiatr Sci*. Apr 15 2025;34:e25.
69. Stefanidou T, Wang J, Morant N, et al. *BMC Psychiatry*. Mar 6 2021;21(1):134.
70. Green MF, Horan WP, Lee J, et al. *Schizophr Bull*. Feb 15 2018;44(2):242–249.
71. Abplanalp SJ, Green MF, Wynn JK, et al. *Schizophrenia (Heidelb)*. Oct 5 2024;10(1):88.
72. Michalska da Rocha B, Rhodes S, Vasilopoulou E, et al. *Schizophr Bull*. Jan 13 2018;44(1):114–125.
73. Parcesepe AM, Cabassa LJ. *Adm Policy Ment Health*. Sep 2013;40(5):384–99.
74. Dubreucq J, Plasse J, Franck N. *Schizophr Bull*. Aug 21 2021;47(5):1261–1287.
75. Fond G, Vidal M, Joseph M, et al. *Mol Psychiatry*. May 2023;28(5):1920–1931.
76. Barlati S, Morena D, Nibbio G, et al. *Schizophr Res*. May 2022;243:364–371.
77. Assefa D, Shibre T, Asher L, et al. *BMC Psychiatry*. Dec 29 2012;12:239.
78. Bilgin Kocak M, Ozturk Atkaya N. *Psychiatry Clin Psychopharmacol*. Jun 2024;34(2):119–126.
79. Gagiu C, Dionisie V, Manea MC, et al. *J Clin Med*. Nov 19 2024;13(22):6959.
80. Hofer A, Mizuno Y, Frajo-Apor B, et al. *Schizophr Res*. Mar 2016;171(1–3):86–91.
81. Lee S, Chiu MY, Tsang A, et al. *Soc Sci Med*. Apr 2006;62(7):1685–96.
82. Langlois S, Pauselli L, Anderson S, et al. *Psychiatry Res*. Apr 2020;286:112855.
83. Stuart H. *Glob Ment Health (Camb)*. 2016;3:e17.
84. Hatzenbuehler ML. *Am Psychol*. Nov 2016;71(8):742–751.
85. Schneider M, Muller CP, Knies AK. *Behav Brain Res*. Oct 28 2022;435:114047.
86. Alegria M, NeMoyer A, Falgas Bague I, et al. *Curr Psychiatry Rep*. Sep 17 2018;20(11):95.
87. Jeste DJ, Thomas ML, Sturm ET, et al. *Schizophr Bull*. Jul 4 2023;49(4):837–850.
88. Shim RS, Compton MT. *Focus (Am Psychiatr Publ)*. Jan 2020;18(1):25–30.
89. Kirkbride JB, Anglin DM, Colman I, et al. *World Psychiatry*. Feb 2024;23(1):58–90.
90. Fond GB, Yon DK, Tran B, et al. *Front Public Health*. 2023;11:1182441.
91. Barry R, Anderson J, Tran L, et al. *JAMA Psychiatry*. Jul 1 2024;81(7):691–699.
92. Correll CU, Xiang P, Sarikonda K, et al. *J Clin Psychiatry*. Aug 21 2024;85(3):24r15316.
93. Tiller J, Maguire T, Newman-Taylor K. *Eur Psychiatry*. Nov 6 2023;66(1):e92.
94. Hahlweg K, Baucom DH. *Eur Arch Psychiatry Clin Neurosci*. Jun 2023;273(4):819–824.
95. Claxton M, Onwumere J, Fornells-Ambrojo M. *Front Psychol*. 2017;8:371.
96. Grover S, Sarkar S, Naskar C, et al. *Asian J Psychiatr*. Apr 2025;106:104421.
97. Manesh AE, Dalvandi A, Zoladl M. *Heliyon*. Mar 2023;9(3):e14333.
98. Prasad F, Hahn MK, Chintoh AF, et al. *Soc Psychiatry Psychiatr Epidemiol*. Jan 2024;59(1):1–23.
99. Chakrabarti S. *World J Psychiatry [Internet]*. 2013;3(4)
100. Citrome L. *J Clin Psychopharmacol*. Apr 2017;37(2):138–147.
101. Dibonaventura M, Gabriel S, Dupclay L, et al. *BMC Psychiatry*. Mar 20 2012;12:20.
102. Tandon R, Lenderking WR, Weiss C, et al. *Ann Gen Psychiatry*. 2020;19:42.
103. Burschinski A, Schneider-Thoma J, Chiocchia V, et al. *World Psychiatry*. Feb 2023;22(1):116–128.
104. Pillinger T, McCutcheon RA, Vano L, et al. *Lancet Psychiatry*. Jan 2020;7(1):64–77.
105. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. *Lancet*. Sep 14 2019;394(10202):939–951.
106. Andrade C. *J Clin Psychiatry*. Jan 30 2023;84(1):23f14790.
107. Citrome L, Eramo A, Francois C, et al. *Neuropsychiatr Dis Treat*. 2015;11:3095–104.
108. Wong KC, Leung PB, Lee BK, et al. *Asian J Psychiatr*. Oct 2024;100:104172.
109. Achtyes E, Simmons A, Skabeev A, et al. *BMC Psychiatry*. Sep 12 2018;18(1):292.
110. Iversen TSJ, Steen NE, Dieset I, et al. *Prog Neuropsychopharmacol Biol Psychiatry*. Mar 2 2018;82:263–271.
111. Thompson JL, Holloway K, Karyczak S, et al. *Psychiatr Serv*. Jul 2022;73(7):787–800.
112. Rosenheck R. *Schizophr Bull*. Jan 3 2023;49(1):7–8.
113. NICE Guidance. Psychosis and schizophrenia in adults: prevention and management. Accessed August 29, 2025. https://www.nice.org.uk/guidance/cg178/chapter/recommendations
114. Vita A, Gaebel W, Mucci A, et al. *Eur Psychiatry*. Sep 5 2022;65(1):e57.
115. Turner DT, van der Gaag M, Karyotaki E, et al. *Am J Psychiatry*. May 2014;171(5):523–38.
116. Berendsen S, Berendse S, van der Torren J, et al. *EClinicalMedicine*. Jan 2024;67:102392.
117. Bighelli I, Rodolico A, Garcia-Mieres H, et al. *Lancet Psychiatry*. Nov 2021;8(11):969–980.
118. Laws KR, Darlington N, Kondel TK, et al. *BMC Psychol*. Jul 17 2018;6(1):32.
119. Lejeune JA, Northrop A, Kurtz MM. *Schizophr Bull*. Jul 8 2021;47(4):997–1006.
120. Kurtz MM, Richardson CL. *Schizophr Bull*. Sep 2012;38(5):1092–104.
121. Keepers GA, Fochtmann LJ, Anzia JM, et al. *Am J Psychiatry*. 2020;177(9):868–872.
122. Meinhart A, Sauve G, Schmueser A, et al. *Transl Psychiatry*. Apr 22 2025;15(1):156.
123. Moritz S, Balzan RP, Menon M, et al. *Expert Rev Neurother*. May 2025;25(5):579–590.
124. Revell ER, Neill JC, Harte M, et al. *Schizophr Res*. Oct 2015;168(1–2):213–22.
125. Cella M, Preti A, Edwards C, et al. *Clin Psychol Rev*. Mar 2017;52:43–51.
126. Vita A, Barlati S, Ceraso A, et al. *JAMA Psychiatry*. Aug 1 2021;78(8):848–858.
127. Taylor R, Cella M, Wykes T. *Behav Modif*. 2025;49(5-6):502-526.
128. Miller WR, Rollnick S. *Motivational Interviewing: Helping People Change, 3rd ed*. The Guilford Press; 2013:xii, 482-xii, 482.
129. Lu EY, Cheng ASK, Tsang HWH, et al. *Front Psychiatry*. 2022;13:899840.
130. Rusch N, Corrigan PW. *Psychiatr Rehabil J*. Summer 2002;26(1):23–32.
131. Chien WT, Mui JH, Cheung EF, et al. *Trials*. Jun 14 2015;16:270.
132. Wang W, Chau AKC, Kong P, et al. *J Clin Psychiatry*. Dec 28 2021;83(1):21r13916.
133. Reddy LF, Glynn SM, McGovern JE, et al. *Am J Psychiatry*. May 1 2023;180(5):367–376.
134. Rummel-Kluge C, Kissling W. *Expert Rev Neurother*. Jul 2008;8(7):1067–77.
135. Hasan A, Falkai P, Wobrock T, et al. *World J Biol Psychiatry*. Feb 2013;14(1):2–44.
136. National Institute for Health and Care Excellence. Psychosis and Schizophrenia in Adults: Prevention and Management. 2014. https://www.nice.org.uk/guidance/cg178
137. Lincoln TM, Wilhelm K, Nestoriuc Y. *Schizophr Res*. Nov 2007;96(1–3):232–45.
138. Xia J, Merinder LB, Belgamwar MR. *Cochrane Database Syst Rev*. Jun 15 2011;2011(6):CD002831.
139. Zhao S, Sampson S, Xia J, et al. *Cochrane Database Syst Rev*. Apr 9 2015;2015(4):CD010823.
140. Kopelowicz A, Liberman RP, Zarate R. *Schizophr Bull*. Oct 2006;32 Suppl

1(Suppl 1):S12–23.
141. Turner DT, McGlanaghy E, Cuijpers P, et al. *Schizophr Bull*. Apr 6 2018;44(3):475–491.
142. Solmi M, Croatto G, Piva G, et al. *Mol Psychiatry*. Jan 2023;28(1):354–368.
143. Stergiopoulos V, Hwang SW, Gozdzik A, et al. *JAMA*. Mar 3 2015;313(9):905–15.
144. Aubry T, Nelson G, Tsemberis S.*Can J Psychiatry*. Nov 2015;60(11):467–74.
145. Hofstra J, van der Velde J, Farkas M, et al. *Psychiatr Rehabil J*. Sep 2023;46(3):173–184.
146. Killaspy H, Baird G, Bromham N, et al. *BMJ*. Jan 12 2021;372:n1.
147. Stergiopoulos V, Hwang SW, Gozdzik A, et al. *JAMA*. Mar 3 2015;313(9):905–15.
148. Bond GR, Drake RE, Becker DR. *Psychiatr Rehabil J*. Spring 2008;31(4):280–90.
149. Frederick DE, VanderWeele TJ. *PLoS One*. 2019;14(2):e0212208.
150. Modini M, Tan L, Brinchmann B, et al. *Br J Psychiatry*. Jul 2016;209(1):14–22.
151. Amaresha AC, Venkatasubramanian G. *Indian J Psychol Med*. Jan 2012;34(1):12–20.
152. Butzlaff RL, Hooley JM. *Arch Gen Psychiatry*. Jun 1998;55(6):547–52.
153. Mueser KT, Penn DL, Addington J, et al. *Psychiatr Serv*. Jul 2015;66(7):680–90.
154. Hogarty GE, Anderson CM, Reiss DJ, et al. *Arch Gen Psychiatry*. Apr 1991;48(4):340–7.
155. Pharoah F, Mari J, Rathbone J, et al. *Cochrane Database Syst Rev*. Dec 8 2010;(12):CD000088.
156. Chien WT, Wong KF. *Psychiatr Serv*. Jul 2007;58(7):1003–6.
157. Rodolico A, Bighelli I, Avanzato C, et al. *Lancet Psychiatry*. Mar 2022;9(3):211–221.
158. Pitschel-Walz G, Leucht S, Bauml J, et al. *Schizophr Bull*. 2001;27(1):73–92.
159. Chien WT, Thompson DR. *Psychiatr Serv*. Oct 2013;64(10):997–1005.
160. Jansen JE, Gleeson J, Bendall S, et al. *Schizophr Res*. Jan 2020;215:25–37.
161. Louise S, Fitzpatrick M, Strauss C, et al. *Schizophr Res*. Feb 2018;192:57–63.
162. Cramer H, Lauche R, Haller H, et al. *Glob Adv Health Med*. Jan 2016;5(1):30–43.
163. Gaudiano BA, Herbert JD, Hayes SC.*Behav Ther*. Dec 2010;41(4):543–54.
164. Kuipers E, Yesufu-Udechuku A, Taylor C, et al. *BMJ*. Feb 12 2014;348:g1173.
165. Reangsing C, Wongsuraprakit S, Punsuwun S, et al. *Psychiatry Res*. Dec 2024;342:116272.
166. Bach P, Hayes SC.*J Consult Clin Psychol*. Oct 2002;70(5):1129–39.
167. Gaudiano BA, Herbert JD.*Behav Res Ther*. Mar 2006;44(3):415–37.
168. Brown E, Shrestha M, Gray R. *Braz J Psychiatry*. May-Jun 2021;43(3):324–336.
169. Chadwick P, Strauss C, Jones AM, et al. *Schizophr Res*. Aug 2016;175(1–3):168–173.
170. Firth J, Carney R, Jerome L, et al. *BMC Psychiatry*. Feb 20 2016;16:36.
171. Firth J, Stubbs B, Rosenbaum S, et al. *Schizophr Bull*. May 1 2017;43(3):546–556.
172. Pajonk FG, Wobrock T, Gruber O, et al. *Arch Gen Psychiatry*. Feb 2010;67(2):133–43.
173. Shimada T, Ito S, Makabe A, et al. *Psychiatry Res*. Aug 2022;314:114656.
174. Guo J, Liu K, Liao Y, et al. *Schizophrenia (Heidelb)*. Jan 2 2024;10(1):2.
175. Bredin SSD, Kaufman KL, Chow MI, et al. *Front Cardiovasc Med*. 2021;8:753117.
176. Perez-Romero N, Campos-Jara C, Pesce C, et al. *Sports (Basel)*. Apr 16 2025;13(4):123.
177. Dai Y, Ding H, Lu X, et al. *Schizophrenia (Heidelb)*. Oct 20 2022;8(1):84.
178. Kimhy D, Lauriola V, Bartels MN, et al. *Schizophr Res*. Apr 2016;172(1–3):213–5.
179. Kimhy D, Vakhrusheva J, Bartels MN, et al. *Schizophr Bull*. Jul 2015;41(4):859–68.
180. Harvey PD, Strassnig M.*World Psychiatry*. Jun 2012;11(2):73–9.
181. Green MF, Horan WP, Lee J. *Nat Rev Neurosci*. Oct 2015;16(10):620–31.
182. McGurk SR, Mueser KT, Pascaris A. *Schizophr Bull*. Oct 2005;31(4):898–909.
183. McGurk SR, Mueser KT, Feldman K, et al. *Am J Psychiatry*. Mar 2007;164(3):437–41.
184. Penn DL, Roberts DL, Combs D, et al. *Psychiatr Serv*. Apr 2007;58(4):449–51.
185. Eassom E, Giacco D, Dirik A, et al. *BMJ Open*. Oct 3 2014;4(10):e006108.
186. Barkhof E, Meijer CJ, de Sonneville LM, et al. *Schizophr Bull*. Nov 2013;39(6):1242–51.
187. Westra HA, Arkowitz H, Dozois DJ. *J Anxiety Disord*. Dec 2009;23(8):1106–17.
188. Nasrallah HA, Lasser R. *J Psychopharmacol*. Nov 2006;20(6 Suppl):57–61.
189. Gurusamy J, Gandhi S, Damodharan D, et al. *Asian J Psychiatr*. Oct 2025;112:104701.
190. Gorwood P, Yildirim M, Madera-McDonough J, et al. *BMC Psychiatry*. Apr 17 2025;25(1):398.
191. Nasrallah H, Morosini P, Gagnon DD. *Psychiatry Res*. Nov 30 2008;161(2):213–24.
192. Üstün TB, World Health Organization. *Measuring Health and Disability: Manual for WHO Disability Assessment Schedule WHODAS 2.0*. WHODAS 20. World Health Organization; 2010.
193. Boehringer Ingelheim and Click Therapeutics. Boehringer and Click Therapeutics' investigational prescription digital therapeutic CT-155 meets primary endpoint in CONVOKE study for negative symptoms in schizophrenia. Press Release. August 7, 2025. Accessed September 24, 2025. https://www.boehringer-ingelheim.com/us/media/press-releases/phase-iii-convoke-study-meets-primary-endpoint